FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:790-800 February 19, 2009 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Gene-expression profiling with the use of DNA microarrays allows measurement of thousands of messenger RNA (mRNA) transcripts in a single experiment. Results of such studies have confirmed that breast cancer is not a single disease with variable morphologic features and biomarkers but, rather, a group of molecularly distinct neoplastic disorders. Profiling results also support the hypothesis that estrogen-receptor (ER)–negative and ER-positive breast cancers originate from distinct cell types and point to biologic processes that govern metastatic progression. Moreover, such profiling has uncovered molecular signatures that could influence clinical care. In this review, we summarize the results of gene-expression studies that . . . [Full Text of this Article]

Molecular Classification of Breast Cancer

Gene-Expression Signatures and Clinical Outcome

Gene-Expression Signatures and Response to Chemotherapy

Readiness of Genomic Signatures for Routine Clinical Use

Conclusions

Source Information

From the Medical Oncology Department, Translational Research Unit, Jules Bordet Institute, Université Libre de Bruxelles, Brussels (C.S.); and the Department of Breast Medical Oncology, the University of Texas M.D. Anderson Cancer Center, Houston (L.P.).

Address reprint requests to Dr. Sotiriou at the Translational Research Unit, Jules Bordet Institute, 121 Blvd. de Waterloo, Brussels 1000, Belgium, or at christos.sotiriou@bordet.be.

This article has been cited by other articles:

• Montemurro, F., Aglietta, M. (2009). Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer 16: 1091-1102 [Abstract] [Full Text]  
• Anderson, W. F., Jatoi, I., Sherman, M. E. (2009). Qualitative Age Interactions in Breast Cancer Studies: Mind the Gap. JCO 27: 5308-5311 [Full Text]  
• Innocenti, F., Schilsky, R. L. (2009). Translating the cancer genome into clinically useful tools and strategies. DMM 2: 426-429 [Full Text]  
• Emery, L. A., Tripathi, A., King, C., Kavanah, M., Mendez, J., Stone, M. D., de las Morenas, A., Sebastiani, P., Rosenberg, C. L. (2009). Early Dysregulation of Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer Progression. Am. J. Pathol. 175: 1292-1302 [Abstract] [Full Text]  
• Burstein, H. J., Souter, I., D'Alessandro, H. A., Sgroi, D. C. (2009). Case 25-2009 -- A 36-Year-Old Woman with Hormone-Receptor-Positive Breast Cancer. NEJM 361: 699-707 [Full Text]  
• Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J., Panel members, (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20: 1319-1329 [Abstract] [Full Text]  
• Singhal, M. K., Raina, V. (2009). Cure from breast cancer, not quite yet but getting there?. Ann Oncol 20: 1291-1292 [Full Text]  
• Guarneri, V., Conte, P. (2009). Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy. The Oncologist 14: 645-656 [Abstract] [Full Text]  
• Pestalozzi, B. C. (2009). Brain metastases and subtypes of breast cancer. Ann Oncol 20: 803-805 [Full Text]